Dual targeting EGFR-MET with osimertinib in combination with savolitinib in MET-amplified, EGFR mutation-positive NSCLC progressed to first line EGFR-TKI showed promising antitumor activity at the interim analysis of the phase 1b SAVANNAH trial [119]. Here, MET is linked to non-small cell lung carcinoma.